PE20151446A1 - Peptidos como agonistas de oxitocina - Google Patents
Peptidos como agonistas de oxitocinaInfo
- Publication number
- PE20151446A1 PE20151446A1 PE2015001058A PE2015001058A PE20151446A1 PE 20151446 A1 PE20151446 A1 PE 20151446A1 PE 2015001058 A PE2015001058 A PE 2015001058A PE 2015001058 A PE2015001058 A PE 2015001058A PE 20151446 A1 PE20151446 A1 PE 20151446A1
- Authority
- PE
- Peru
- Prior art keywords
- lower alkyl
- hydrogen
- hydroxy
- cycloalkyl
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invencion se refiere a compuestos de la formula (I); en la que: R1 es hidroxi o amino; R2 es sec-butilo o isobutilo; R3 es alquilo inferior, alquilo inferior sustituido por hidroxi, -(CH2)2C(O)-NH2, -(CH2)3-NH2 o -CH2-grupo heterociclico aromatico de cinco eslabones; R4 es hidrogeno o alquilo inferior; R5 es hidrogeno o alquilo inferior; o R4 y R5 junto con los atomos de N y C a los que estan unidos pueden formar un anillo de pirrolidina, opcionalmente sustituido por hidroxi o halogeno, un anillo de piperidina o un anillo de azetidina; R6 es hidrogeno, alquilo inferior, alquilo inferior sustituido por hidroxi, -(CH2)2C(O)OH, -(CH2)2C(O)NH2, bencilo opcionalmente sustituido por amino o hidroxi, -CH2-grupo heterociclico aromatico de cinco eslabones, indolilo, -CH2-ciclo alquilo, cicloalquilo, -(CH2)2-S-alquilo inferior o es - (CH2)1-4-NH2; R6' es hidrogeno o alquilo inferior; o R6 y R6' juntos son cicloalquilo; X es -C(O) -CHR-NR' -C(O)-; R/R' con independencia entre si son hidrogeno o alquilo inferior; m es el numero 2; "o" es el numero 0 o 1; o a una sal de adicion de acido farmaceuticamente aceptable, a una mezcla racemica o a sus enantiomeros correspondientes y/o isomeros opticos de los mismos. Dichos compuestos son agonistas de receptores de oxitocina y son utiles en el tratamiento del autismo, el estres, incluido el trastorno del estres postraumatico, la ansiedad, incluidos los trastornos de ansiedad y la depresion, la esquizofrenia y trastornos psiquiatricos
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12199012 | 2012-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20151446A1 true PE20151446A1 (es) | 2015-09-28 |
Family
ID=47471593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015001058A PE20151446A1 (es) | 2012-12-21 | 2013-12-17 | Peptidos como agonistas de oxitocina |
Country Status (34)
Country | Link |
---|---|
US (1) | US9868766B2 (es) |
EP (1) | EP2935312B1 (es) |
JP (1) | JP6067878B2 (es) |
KR (1) | KR101819804B1 (es) |
CN (1) | CN104870466B (es) |
AR (1) | AR094225A1 (es) |
AU (1) | AU2013363768B2 (es) |
BR (1) | BR112015014010A2 (es) |
CA (1) | CA2895150C (es) |
CL (1) | CL2015001724A1 (es) |
CR (1) | CR20150271A (es) |
DK (1) | DK2935312T3 (es) |
EA (1) | EA026687B1 (es) |
ES (1) | ES2690317T3 (es) |
HK (1) | HK1208477A1 (es) |
HR (1) | HRP20181569T1 (es) |
HU (1) | HUE039848T2 (es) |
IL (1) | IL239519A (es) |
LT (1) | LT2935312T (es) |
MA (1) | MA38272A1 (es) |
MX (1) | MX358684B (es) |
MY (1) | MY176398A (es) |
NZ (1) | NZ708175A (es) |
PE (1) | PE20151446A1 (es) |
PH (1) | PH12015501145B1 (es) |
PL (1) | PL2935312T3 (es) |
PT (1) | PT2935312T (es) |
RS (1) | RS57690B1 (es) |
SG (1) | SG11201504883PA (es) |
SI (1) | SI2935312T1 (es) |
TW (1) | TWI558726B (es) |
UA (1) | UA119034C2 (es) |
WO (1) | WO2014095773A1 (es) |
ZA (1) | ZA201504186B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
KR101819804B1 (ko) | 2012-12-21 | 2018-01-17 | 에프. 호프만-라 로슈 아게 | 옥시토신 작용제로서의 펩타이드 |
EP3421482A1 (en) | 2012-12-21 | 2019-01-02 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
KR102116107B1 (ko) | 2013-12-30 | 2020-05-28 | 삼성디스플레이 주식회사 | 표시 장치 |
WO2015106200A2 (en) | 2014-01-10 | 2015-07-16 | Cornell University | Dipeptides as inhibitors of human immunoproteasomes |
PE20161559A1 (es) | 2014-06-03 | 2017-01-12 | Hoffmann La Roche | Peptidos como agonistas de la oxitocina |
AP2016009605A0 (en) | 2014-06-17 | 2016-12-31 | Pfizer | Substituted dihydroisoquinolinone compounds |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
TR201815872T4 (tr) * | 2014-08-07 | 2018-11-21 | Hoffmann La Roche | Oksitosin analoglarının hazırlanması için prosesler. |
WO2016028571A2 (en) * | 2014-08-18 | 2016-02-25 | Cornell University | Dipeptidomimetics as inhibitors of human immunoproteasomes |
US10441627B2 (en) | 2014-09-19 | 2019-10-15 | Ferring B.V. | Method of treating prader-willi syndrome |
EP3362754B1 (en) | 2015-10-15 | 2021-12-22 | Cornell University | Proteasome inhibitors and uses thereof |
EP3694605A4 (en) | 2017-10-11 | 2021-10-27 | Cornell University | PEPTIDOMIMETIC PROTEASOME INHIBITORS |
WO2020061414A1 (en) | 2018-09-20 | 2020-03-26 | Levo Therapeutics, Inc. | Stable intranasal formulations of carbetocin |
TW202034899A (zh) | 2018-09-20 | 2020-10-01 | 克里斯托弗 S 布萊恩特 | 卡貝縮宮素藥品及其製備方法 |
WO2021126990A1 (en) * | 2019-12-16 | 2021-06-24 | The Scripps Research Institute | Oxytocin derivatives with improved properties |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8673841B2 (en) | 2008-03-31 | 2014-03-18 | Ferring B.V. | Oxytocin analogues |
TWI463990B (zh) * | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
ES2509270T3 (es) * | 2009-10-01 | 2014-10-17 | The University Of Sydney | Terapia y prevención del alcoholismo |
KR101819804B1 (ko) | 2012-12-21 | 2018-01-17 | 에프. 호프만-라 로슈 아게 | 옥시토신 작용제로서의 펩타이드 |
-
2013
- 2013-12-17 KR KR1020157016376A patent/KR101819804B1/ko active IP Right Grant
- 2013-12-17 CN CN201380066617.7A patent/CN104870466B/zh not_active Expired - Fee Related
- 2013-12-17 WO PCT/EP2013/076783 patent/WO2014095773A1/en active Application Filing
- 2013-12-17 AU AU2013363768A patent/AU2013363768B2/en not_active Ceased
- 2013-12-17 MX MX2015007365A patent/MX358684B/es active IP Right Grant
- 2013-12-17 DK DK13814079.3T patent/DK2935312T3/en active
- 2013-12-17 PL PL13814079T patent/PL2935312T3/pl unknown
- 2013-12-17 ES ES13814079.3T patent/ES2690317T3/es active Active
- 2013-12-17 HU HUE13814079A patent/HUE039848T2/hu unknown
- 2013-12-17 RS RS20181124A patent/RS57690B1/sr unknown
- 2013-12-17 PE PE2015001058A patent/PE20151446A1/es unknown
- 2013-12-17 SI SI201331190T patent/SI2935312T1/sl unknown
- 2013-12-17 MA MA38272A patent/MA38272A1/fr unknown
- 2013-12-17 SG SG11201504883PA patent/SG11201504883PA/en unknown
- 2013-12-17 EP EP13814079.3A patent/EP2935312B1/en active Active
- 2013-12-17 JP JP2015548420A patent/JP6067878B2/ja not_active Expired - Fee Related
- 2013-12-17 BR BR112015014010A patent/BR112015014010A2/pt not_active IP Right Cessation
- 2013-12-17 CA CA2895150A patent/CA2895150C/en not_active Expired - Fee Related
- 2013-12-17 MY MYPI2015001585A patent/MY176398A/en unknown
- 2013-12-17 LT LTEP13814079.3T patent/LT2935312T/lt unknown
- 2013-12-17 UA UAA201506906A patent/UA119034C2/uk unknown
- 2013-12-17 NZ NZ708175A patent/NZ708175A/en not_active IP Right Cessation
- 2013-12-17 EA EA201591078A patent/EA026687B1/ru not_active IP Right Cessation
- 2013-12-17 PT PT13814079T patent/PT2935312T/pt unknown
- 2013-12-20 TW TW102147655A patent/TWI558726B/zh not_active IP Right Cessation
- 2013-12-20 AR ARP130104962A patent/AR094225A1/es unknown
-
2015
- 2015-05-21 CR CR20150271A patent/CR20150271A/es unknown
- 2015-05-22 PH PH12015501145A patent/PH12015501145B1/en unknown
- 2015-06-10 ZA ZA2015/04186A patent/ZA201504186B/en unknown
- 2015-06-18 US US14/743,009 patent/US9868766B2/en active Active
- 2015-06-18 CL CL2015001724A patent/CL2015001724A1/es unknown
- 2015-06-18 IL IL239519A patent/IL239519A/en active IP Right Grant
- 2015-09-18 HK HK15109189.5A patent/HK1208477A1/xx not_active IP Right Cessation
-
2018
- 2018-10-02 HR HRP20181569TT patent/HRP20181569T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20151446A1 (es) | Peptidos como agonistas de oxitocina | |
PH12016502251A1 (en) | Peptides as oxytocin agonists | |
CO2017011174A2 (es) | Derivados de etileno como moduladores metabotropicos de receptores de glutamato | |
EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
MX2015017491A (es) | Derivados de indolin-2-ona o pirrolo-piridin/pirimidin-2-ona. | |
CY1119326T1 (el) | Φαινυλο-3-αζα-δικυκλο[3.1.0]εξ-3-υλο-μεθανονες και η χρηση αυτων ως φαρμακο | |
AR078756A1 (es) | Moduladores alostericos positivos (map) | |
DOP2015000009A (es) | Antagonistas del receptor de 5-ht3 | |
PH12016502232A1 (en) | Peptides as oxytocin agonists | |
ECSP14013296A (es) | Derivados de etinilo | |
AR074511A1 (es) | Proceso para la fabricacion de derivados del acido 5-metoximetilpiridin-2,3-dicarboxilico sustituido | |
AR086036A1 (es) | DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5) | |
AR077960A1 (es) | Derivados de benzamida n-sustituidos como inhibidores del transportador de glicina 1 (glyt-1) | |
CO6341621A2 (es) | Piperidinas arilamino y heteroarilamino sustituidas como inhibidores de glyt-1 | |
AR083718A1 (es) | Fenil cicloalquil pirrolidina (piperidina) espirolactamas y amidas sustituidas, preparacion y uso terapeutico de las mismas | |
CR20130476A (es) | Derivados de pirazolidin-3-ona | |
CR20150158A (es) | Derivados de etinilo como moduladores de receptor de actividad mglur5 | |
PE20150685A1 (es) | Pirimidinas de ariletinilo | |
AR081382A1 (es) | Derivados de n-heterocicloalquil bipirrolidinilfenil amida sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central. | |
CO6491024A2 (es) | Acido (s) -2-bencil-3- ( (3r, 4r)-4- (3-carbamoilfenil)-3, 4-dimetilpiperidinil) propanoico y sales del mismo como antagonistas de receptores opioides | |
AR100532A1 (es) | Derivados de indolín-2-ona y 1,3-dihidro-pirrolo[3,2-c]piridín-2-ona | |
AR081384A1 (es) | N- fenil espirolactama bipirrolidinas sustituidas, preparacion y uso terapeutico de las mismas | |
AR081383A1 (es) | N-heteroaril bipirrolidin carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de enfermedades del sistema nervioso central. | |
TH167739B (th) | เปปไทด์เป็นตัวทำการออกซีโทซิน |